Drug Profile
Research programme: pathfinder cell therapies - Pathfinder Cell Therapy
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Pathfinder Cell Therapy
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Ischaemia; Osteoarthritis; Reperfusion injury
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (IV)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ischaemia in USA (IV)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Osteoarthritis in USA